128 related articles for article (PubMed ID: 35674780)
1. Surveillance after Complete Response to First-Line Chemotherapy in Patients with Metastatic Nonseminomatous Germ Cell Tumor.
King JM; Althouse S; Cary C; Masterson T; Foster RS; Ashkar R; Hanna NH; Einhorn LH; Adra N
J Urol; 2022 Sep; 208(3):641-649. PubMed ID: 35674780
[TBL] [Abstract][Full Text] [Related]
2. Long-term Surveillance of Patients with Complete Response Following Chemotherapy for Metastatic Nonseminomatous Germ Cell Tumor.
Nason GJ; Jewett MAS; Bostrom PJ; Goldberg H; Hansen AR; Bedard PL; Sturgeon J; Warde P; Chung P; Anson-Cartwright L; Sweet J; Atenafu EG; O'Malley M; Hamilton RJ
Eur Urol Oncol; 2021 Apr; 4(2):289-296. PubMed ID: 32907779
[TBL] [Abstract][Full Text] [Related]
3. Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study.
Antonelli L; Ardizzone D; Ravi P; Bagrodia A; Mego M; Daneshmand S; Nicolai N; Nazzani S; Giannatempo P; Franza A; Heidenreich A; Paffenholz P; Saoud R; Eggener S; Ho M; Oswald N; Olson K; Tryakin A; Fedyanin M; Naoun N; Javaud C; Fizazi K; King JM; Adra N; Douglawi A; Cary C; Sweeney C; Fankhauser CD
Eur J Cancer; 2023 Mar; 182():144-154. PubMed ID: 36787661
[TBL] [Abstract][Full Text] [Related]
4. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.
Gillessen S; Sauvé N; Collette L; Daugaard G; de Wit R; Albany C; Tryakin A; Fizazi K; Stahl O; Gietema JA; De Giorgi U; Cafferty FH; Hansen AR; Tandstad T; Huddart RA; Necchi A; Sweeney CJ; Garcia-Del-Muro X; Heng DYC; Lorch A; Chovanec M; Winquist E; Grimison P; Feldman DR; Terbuch A; Hentrich M; Bokemeyer C; Negaard H; Fankhauser C; Shamash J; Vaughn DJ; Sternberg CN; Heidenreich A; Beyer J;
J Clin Oncol; 2021 May; 39(14):1563-1574. PubMed ID: 33822655
[TBL] [Abstract][Full Text] [Related]
5. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007
[TBL] [Abstract][Full Text] [Related]
6. Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors.
Albany C; Adra N; Snavely AC; Cary C; Masterson TA; Foster RS; Kesler K; Ulbright TM; Cheng L; Chovanec M; Taza F; Ku K; Brames MJ; Hanna NH; Einhorn LH
Ann Oncol; 2018 Feb; 29(2):341-346. PubMed ID: 29140422
[TBL] [Abstract][Full Text] [Related]
7. Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery.
Kollmannsberger C; Daneshmand S; So A; Chi KN; Murray N; Moore C; Hayes-Lattin B; Nichols C
J Clin Oncol; 2010 Feb; 28(4):537-42. PubMed ID: 20026807
[TBL] [Abstract][Full Text] [Related]
8. Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group.
Aparicio J; Sánchez-Muñoz A; Ochenduszko S; Gumà J; Fernández-Aramburo A; García Del Muro X; Quiroga V; Sastre J; Alonso-Gordoa T; Sagastibelza N; Maroto P; Gómez de Liaño A; Vázquez S; Diz P; Durán I; Domenech M; Pinto A; Hernández A; González-Billalabeitia E; Terrasa J
J Urol; 2019 Oct; 202(4):742-747. PubMed ID: 31163007
[TBL] [Abstract][Full Text] [Related]
9. Early resection of residual tumor during cisplatin, vinblastine, bleomycin combination chemotherapy in stage III and bulky stage II nonseminomatous testicular cancer.
Pizzocaro G; Salvioni R; Pasi M; Zanoni F; Milani A; Pilotti S; Monfardini S
Cancer; 1985 Jul; 56(2):249-55. PubMed ID: 2408728
[TBL] [Abstract][Full Text] [Related]
10. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group.
Fizazi K; Tjulandin S; Salvioni R; Germà-Lluch JR; Bouzy J; Ragan D; Bokemeyer C; Gerl A; Fléchon A; de Bono JS; Stenning S; Horwich A; Pont J; Albers P; De Giorgi U; Bower M; Bulanov A; Pizzocaro G; Aparicio J; Nichols CR; Théodore C; Hartmann JT; Schmoll HJ; Kaye SB; Culine S; Droz JP; Mahé C
J Clin Oncol; 2001 May; 19(10):2647-57. PubMed ID: 11352956
[TBL] [Abstract][Full Text] [Related]
11. Late relapse of metastatic testicular nonseminomatous germ cell cancer: surgery is needed for cure.
Geldart TR; Gale J; McKendrick J; Kirby J; Mead G
BJU Int; 2006 Aug; 98(2):353-8. PubMed ID: 16879677
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology of male seminomatous and nonseminomatous germ cell tumors and response to first-line chemotherapy from a tertiary cancer center in India.
Joshi A; Zanwar S; Shetty N; Patil V; Noronha V; Bakshi G; Prakash G; Menon S; Prabhash K
Indian J Cancer; 2016; 53(2):313-316. PubMed ID: 28071636
[TBL] [Abstract][Full Text] [Related]
13. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
[TBL] [Abstract][Full Text] [Related]
14. Dose-reduced first cycle of chemotherapy for prevention of life-threatening acute complications in nonseminomatous germ cell tumor patients with ultra high tumor markers and/or poor performance status.
Tryakin A; Fedyanin M; Bulanov A; Kashia S; Kurmukov I; Matveev V; Fainstein I; Gordeeva O; Zakharova T; Tjulandin S
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1817-1823. PubMed ID: 29974210
[TBL] [Abstract][Full Text] [Related]
15. First-line salvage treatment options for germ cell tumor patients failing stage-adapted primary treatment : A comprehensive review compiled by the German Testicular Cancer Study Group.
Pfister D; Oechsle K; Schmidt S; Busch J; Bokemeyer C; Heidenreich A; Heinzelbecker J; Ruf C; Winter C; Zengerling F; Kliesch S; Albers P; Oing C
World J Urol; 2022 Dec; 40(12):2853-2861. PubMed ID: 35226138
[TBL] [Abstract][Full Text] [Related]
16. Surveillance of postchemotherapy subcentimeter residual retroperitoneal mass in metastatic nonseminomatous germ cell tumor: Does how you measure matter?
Cotner CE; Hilton S; Mamtani R; Guzzo T; Vaughn DJ
Urol Oncol; 2021 Feb; 39(2):136.e11-136.e17. PubMed ID: 33308971
[TBL] [Abstract][Full Text] [Related]
17. Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers.
Wood DP; Herr HW; Motzer RJ; Reuter V; Sogani PC; Morse MJ; Bosl GJ
Cancer; 1992 Nov; 70(9):2354-7. PubMed ID: 1382832
[TBL] [Abstract][Full Text] [Related]
18. Vinblastine, actinomycin D, bleomycin, cyclophosphamide and cis-platinum for advanced germ cell testis tumors: Brazilian experience.
Srougi M; Simon SD; de Góes GM
J Urol; 1985 Jul; 134(1):65-9. PubMed ID: 2409300
[TBL] [Abstract][Full Text] [Related]
19. Reliability of Serum Tumor Marker Measurement to Diagnose Recurrence in Patients with Clinical Stage I Nonseminomatous Germ Cell Tumors Undergoing Active Surveillance: A Systematic Review.
Chakiryan NH; Dahmen A; Cucchiara V; Briganti A; Montorsi F; Salonia A; Spiess PE; Necchi A
J Urol; 2021 Jun; 205(6):1569-1576. PubMed ID: 33617328
[TBL] [Abstract][Full Text] [Related]
20. Outcome of patients with stage II and III nonseminomatous germ cell tumors: results of a single center.
Ataergin S; Ozet A; Arpaci F; Kilic S; Beyzadeoglu M; Komurcu S
Indian J Cancer; 2007; 44(1):6-11. PubMed ID: 17401218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
